As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

Glioblastoma (GBM) is the most common kind of malignant brain tumor in adults. In recent years, the tumor microenvironment ...

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...

Marker Therapeutics was awarded a $2 million grant from NIH Small Business Innovation Research Program (SBIR) to support the clinical investigation of MT-601 in patients with lymphoma who have ...

T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...

Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...